Hypoglycemia News and Research RSS Feed - Hypoglycemia News and Research

Hypoglycemia, also called low blood glucose or low blood sugar, occurs when blood glucose drops below normal levels. Glucose, an important source of energy for the body, comes from food. Carbohydrates are the main dietary source of glucose.
Single injection of protein FGF1 enough to restore blood sugar levels

Single injection of protein FGF1 enough to restore blood sugar levels

In mice with diet-induced diabetes—the equivalent of type 2 diabetes in humans—a single injection of the protein FGF1 is enough to restore blood sugar levels to a healthy range for more than two days. [More]
Afrezza gets FDA approval to improve glycemic control in adults with diabetes mellitus

Afrezza gets FDA approval to improve glycemic control in adults with diabetes mellitus

The U.S. Food and Drug Administration today approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Afrezza is a rapid-acting inhaled insulin that is administered at the beginning of each meal, or within 20 minutes after starting a meal. [More]
Animas' predictive algorithm technology maintains glucose above hypoglycemic levels

Animas' predictive algorithm technology maintains glucose above hypoglycemic levels

Animas Corporation today shared encouraging results from its predictive hypoglycemia-minimizing algorithm in development. [More]
Bionic pancreas device controls blood sugar in patients with type 1 diabetes

Bionic pancreas device controls blood sugar in patients with type 1 diabetes

The latest version of a bionic pancreas device has been successfully tested in two five-day clinical trials - one in adults, the other in adolescents - that imposed minimal restrictions on patient activities. [More]
American Association of Diabetes Educators suggests tips for safe travel

American Association of Diabetes Educators suggests tips for safe travel

AAA estimates 36.1 million people will travel this Memorial Day weekend. If diabetes is your constant companion, that doesn't mean you can't enjoy traveling, whether traversing America in an RV or flying to the far reaches of the globe. Ensuring you stay healthy and keep your glucose levels on an even keel does require a little bit of organization and planning ahead, though. [More]
Chemists develop new chemical analysis method to detect counterfeit medicines

Chemists develop new chemical analysis method to detect counterfeit medicines

Researchers at the University of Montreal have developed an improved chemical analysis method that is more efficient and faster in detecting counterfeit medicines, which have skyrocketed in recent years. [More]
Breastfeeding initiation and success impacted by diabetes status of mother

Breastfeeding initiation and success impacted by diabetes status of mother

Women diagnosed with diabetes before or during pregnancy are less likely to initiate and continue breastfeeding their newborns than women without diabetes, a new study suggests. Led by clinician-scientists in The Research Institute at Nationwide Children's Hospital and collaborating institutions, the findings point to areas for improved prenatal and postnatal education of women with diabetes. [More]
Data from phase III trials supports safety, efficacy of linagliptin in treating T2D in African-American adults

Data from phase III trials supports safety, efficacy of linagliptin in treating T2D in African-American adults

Data from a retrospective pooled analysis of eight phase III trials (two 18-week and six 24-week) of linagliptin 5 mg once-daily, showed reductions from baseline A1c at 18 (eight trials) and 24 (six trials) weeks compared to placebo in African-American adults with type 2 diabetes (T2D), [More]
Isis Pharmaceuticals reports positive data from ISIS-GCGRRx Phase 2 study in patients with type 2 diabetes

Isis Pharmaceuticals reports positive data from ISIS-GCGRRx Phase 2 study in patients with type 2 diabetes

Isis Pharmaceuticals, Inc. announced today positive data from a Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on stable metformin therapy. [More]
Report focuses on behavioral issues linked with patients' self-management of type 2 diabetes

Report focuses on behavioral issues linked with patients' self-management of type 2 diabetes

Clinical Therapeutics features a special report in its April issue focusing primarily on the behavioral issues associated with patients' self-management of type 2 diabetes. [More]
Monarch Medical Technologies gets FDA clearance for new glucose management solution

Monarch Medical Technologies gets FDA clearance for new glucose management solution

Monarch Medical Technologies, the pioneer and leader in mitigating risk associated with drugs and processes of concern in hospitalized patients, today announced the U.S. Food and Drug Administration clearance of its new glucose management solution, EndoTool IV. [More]
FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

GlaxoSmithKline plc today announced that the US Food and Drug Administration has approved Tanzeum (albiglutide) for injection, for subcutaneous use, as a once-weekly treatment for type 2 diabetes. Tanzeum has been approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [More]
Adocia announces positive results from BioChaperone Lispro phase IIa clinical trial

Adocia announces positive results from BioChaperone Lispro phase IIa clinical trial

Adocia announces positive results from a phase IIa clinical trial evaluating its innovative ultra-fast formulation of insulin Lispro in comparison to Eli Lilly’s Humalog commercial insulin. Adocia’s formulation incorporates proprietary BioChaperone technology which enables accelerated absorption of prandial insulins. Humalog, which is now off-patent, has annual sales of USD 2.6 billion. [More]

Common treatment for type 2 diabetes could cause longer-than-normal periods of hypoglycemia

Researchers at the University of Adelaide have discovered that a common treatment for people with type 2 diabetes could cause longer-than-normal periods of the low blood sugar reaction hypoglycemia, which may result in increased health risks to people with diabetes. [More]
Halozyme meets primary endpoint in Hylenex CONSISTENT 1 trial

Halozyme meets primary endpoint in Hylenex CONSISTENT 1 trial

Halozyme Therapeutics, Inc. today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment. [More]
Aleglitazar drug does not reduce risk of cardiovascular events in patients with type 2 diabetes

Aleglitazar drug does not reduce risk of cardiovascular events in patients with type 2 diabetes

Use of the drug aleglitazar, which has shown the ability to lower glucose levels and have favorable effects on cholesterol, did not reduce the risk of cardiovascular death, heart attack or stroke among patients with type 2 diabetes and recent heart attack or unstable angina, according to a JAMA study released online to coincide with presentation at the 2014 American College of Cardiology Scientific Sessions. [More]
Study links effect of gastric bypass surgery on glucose metabolism and islet function in hypoglycemia patients

Study links effect of gastric bypass surgery on glucose metabolism and islet function in hypoglycemia patients

University of Cincinnati (UC) researchers have discovered that altered islet cell function and reduced insulin clearance contribute to excessive post-meal insulin response in patients experiencing low blood sugar symptoms (hypoglycemia) following gastric bypass surgery. [More]
BD Micro-Fine Ultra Pen Needle with Pentapoint technology launched in the UK and Ireland

BD Micro-Fine Ultra Pen Needle with Pentapoint technology launched in the UK and Ireland

BD (Becton, Dickinson and Company), a leading global medical technology company, announced today the launch in the UK and Ireland of BD Micro-Fine Ultra with 5-bevel needle technology, clinically demonstrated to improve injection comfort for diabetes patients, and enhancing the injection advantages of the current BD Micro-Fine+ Pen Needle. [More]
Pierre Fabre Dermatologie receives FDA marketing authorization for pediatric drug Hemangeol

Pierre Fabre Dermatologie receives FDA marketing authorization for pediatric drug Hemangeol

Pierre Fabre Dermatologie has obtained marketing authorization from the FDA for the pediatric drug Hemangeol (propranolol hydrochloride), which is the first and only approved treatment for "proliferating infantile hemangioma requiring systemic therapy". [More]
Jersey Shore University earns Joint Commission's Gold Seal of Approval for inpatient diabetes care program

Jersey Shore University earns Joint Commission's Gold Seal of Approval for inpatient diabetes care program

Jersey Shore University Medical Center has earned The Joint Commission's Gold Seal of Approval™ for its inpatient diabetes care program by providing the best care available for patients with diabetes, and successfully meeting The Joint Commission's national standards for health care quality and safety. [More]